Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.32 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.32 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.32 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.32 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16829183 | 0.86 | KEAP1 (0.50) | ALOX15ACE2SIGMAR1KEAP1SMN1; SMN2 | |
| SCHEMBL295704 | 0.75 | — | — | |
| SCHEMBL12311431 | 0.75 | DRD2 (0.36) | SIGMAR1 | |
| SCHEMBL11311 | 0.75 | ALDH1A1 (0.43) | SIGMAR1 | |
| SCHEMBL357824 | 0.75 | — | — | |
| SCHEMBL3975418 | 0.74 | ALOX15 (1.00) | ALOX15ACE2SIGMAR1KEAP1SMN1; SMN2 | |
| SCHEMBL179843 | 0.74 | ALOX15 (1.00) | ALOX15ACE2SIGMAR1KEAP1SMN1; SMN2 | |
| SCHEMBL242967 | 0.74 | — | — | |
| SCHEMBL11501587 | 0.72 | ALOX15 (0.93) | ALOX15ACE2SIGMAR1KEAP1SMN1; SMN2 | |
| SCHEMBL11541738 | 0.72 | ALOX15 (0.93) | ALOX15ACE2SIGMAR1KEAP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250057960-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | BioNTech SE (DE) | 2025-02-20 | — | — | US | disclosed |
| US-20250057944-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) | 2025-02-20 | — | — | US | disclosed |
| US-20240425541-A1 | OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES | BioNTech SE (DE) | 2024-12-26 | — | — | US | disclosed |
| CN-118414171-A | Oligosaccharide complexes and uses | 生物技术公司 | 2024-07-30 | — | — | CN | disclosed |
| CN-118401538-A | Oligosaccharide compounds and complexes | 生物技术公司 | 2024-07-26 | — | — | CN | disclosed |
| EP-4401838-A1 | OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES | BioNTech SE (DE) | 2024-07-24 | — | — | EP | disclosed |
| EP-4401789-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | BioNTech SE (DE) | 2024-07-24 | — | — | EP | disclosed |
| EP-4401788-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | BioNTech SE (DE) | 2024-07-24 | — | — | EP | disclosed |
| CN-118369122-A | Oligosaccharide complex and use thereof | 生物技术公司 | 2024-07-19 | — | — | CN | disclosed |
| EP-4286003-A1 | OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES | BioNTech SE (DE) | 2023-12-06 | — | — | EP | disclosed |
| WO-2012038904-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-03-29 | — | — | WO | disclosed |
| US-20120053209-A1 | ANTICANCER COMPOUNDS, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-03-01 | — | — | US | disclosed |
| US-20120053170-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS | SANOFI (FR) | 2012-03-01 | — | — | US | disclosed |
| EP-2411364-A1 | ANTICANCER COMPOUNDS, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-01 | — | — | EP | disclosed |
| EP-2411367-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-01 | — | — | EP | disclosed |
| EP-2411368-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS | SANOFI (FR) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010109115-A1 | ANTICANCER COMPOUNDS, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010109122-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010109123-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | WO | disclosed |
| US-7217447-B2 | Ink-jet recording sheet | FUJIFILM CORPORATION (JP) | 2007-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250057944-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | FUT6, NSUN3, OSTC | ALOX15 4137/4885ACE2 3614/4885SIGMAR1 3048/4885 |
| US-20250057960-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | CD4, FUT6, UGCG | ALOX15 1466/4885ACE2 2776/4885SIGMAR1 2333/4885 |
| US-20120053170-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS | NAMPT, NNT, NQO1 | ALOX15 1366/4885ACE2 3599/4885SIGMAR1 4757/4885 |
| US-20240425541-A1 | OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES | OSTC, SNRPA, RNASE1 | ALOX15 2873/4885ACE2 2320/4885SIGMAR1 3795/4885 |
| US-20120053209-A1 | ANTICANCER COMPOUNDS, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | NAMPT, NQO1, NADK | ALOX15 1418/4885ACE2 3528/4885SIGMAR1 4634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.